Moffitt logo

Clinical Trials Search

Clinical Trial 20728

Cancer Type: Multiple
Study Type: Treatment
NCT#: NCT04338360

Phase: N/A
Prinicipal Investigator:

Call 813-745-6100
or 1-800-679-0775 Learn More
Overview

Study Title

Expanded Access to Convalescent Plasma for the Treatment of Patients with COVID-19

Summary

This expanded access program will provide access to investigational convalescent plasma for patients in acute care facilities infected with SARS-CoV-2 who have severe or life-threatening COVID-19, or who are judged by a healthcare provider to be at high risk of progression to severe or life-threatening disease.

Objective

Treatments

Therapies

Medications

Inclusion Criteria

  • Age at least 18 years
  • Laboratory confirmed or clinically suspected diagnosis of infection with SARS-CoV-2
  • Admitted to an acute care facility for the treatment of COVID-19 complications
  • Severe or life threatening COVID-19, or judged by the treating provider to be at high risk of progression to severe or life-threatening disease
  • Informed consent provided by the patient or healthcare proxy
  • Severe COVID-19 is defined by one or more of the following:
  • > dyspnea
  • respiratory frequency> 30/min
  • blood oxygen saturation > partial pressure of arterial oxygen to fraction of inspired oxygen ratio > lung infiltrates > 50% within 24 to 48 hours
  • Life-threatening COVID-19 is defined as one or more of the following:
  • respiratory failure
  • septic shock
  • multiple organ dysfunction or failure

  • If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.